Skip header and navigation

Refine By

   MORE

15 records – page 1 of 2.

Biophysiological effects of Ukrain therapy in a patient with breast cancer (case report).

https://arctichealth.org/en/permalink/ahliterature22882
Source
Drugs Exp Clin Res. 1996;22(3-5):247-54
Publication Type
Article
Date
1996
Author
E. Schramm
J W Nowicky
Y. Godysh
Author Affiliation
Ukrainian Anti-Cancer Institute, Vienna, Austria.
Source
Drugs Exp Clin Res. 1996;22(3-5):247-54
Date
1996
Language
English
Publication Type
Article
Keywords
Alkaloids - adverse effects - therapeutic use
Antineoplastic Agents - adverse effects - therapeutic use
Aspartate Aminotransferases - blood
Blood Glucose - drug effects
Blood Pressure - drug effects
Blood Proteins - metabolism
Body Temperature - drug effects
Breast Neoplasms - blood - drug therapy - physiopathology
Electrolytes - blood
Female
Humans
Leukocytes - drug effects
Middle Aged
Pulse - drug effects
Abstract
The effects on different biophysiological parameters and subjective impressions were studied in a patient with breast cancer who was not previously given any therapy before receiving Ukrain. Daily measurements of pulse, blood pressure, temperature and various laboratory examinations were carried out. Development and course of subjective and objective phenomena seem to be typical for patients in whom Ukrain could induce long-term complete remission. The patient described here has had to data 12 years without any oncopathological symptoms.
PubMed ID
8899341 View in PubMed
Less detail

Chelidonium majus L. (Ukrain) in the treatment of cancer patients.

https://arctichealth.org/en/permalink/ahliterature24635
Source
Drugs Exp Clin Res. 1992;18 Suppl:73-7
Publication Type
Article
Date
1992
Author
A. Lohninger
F. Hamler
Author Affiliation
2nd Dept. of Obstetrics and Gynaecology, Vienna Medical School, Austria.
Source
Drugs Exp Clin Res. 1992;18 Suppl:73-7
Date
1992
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - drug therapy
Aged
Alkaloids - adverse effects - therapeutic use
Antineoplastic Agents, Phytogenic - adverse effects - therapeutic use
Bone Neoplasms - drug therapy - radiography - secondary
Breast Neoplasms - complications - drug therapy
Child
Colonic Neoplasms - drug therapy
Female
Humans
Middle Aged
Neoplasms - drug therapy - radiography
Sarcoma, Ewing's - drug therapy - radiography
Abstract
Ukrain, a semi-synthetic thiophosphoric acid compound of alkaloid chelidonine isolated from Chelidonium Majus L., Tris(2-([5bS-(5ba,6b,12ba)]-5b,6,7,12b,13,14- Hexahydro-13-methyl][1,3]-benzodioxolo[5,6-c]-1,3-dioxolo[4, 5- i]phenanthridinium-6-ol]-Ethaneaminyl) Phosphinesulfide 6HCl, causes a regression of tumours and metastases in many oncological patients. More than 400 documented patients with various carcinomas in different stages of development have been treated with Ukrain. The authors report on only three different cases treated with preparation Ukrain. Ukrain can be helpful in improving the general condition and prolonging life by reduction of the tumour progression and its immunomodulating effect on the organism.
PubMed ID
1305049 View in PubMed
Less detail

Clinical studies of Ukrain in terminal cancer patients (phase II).

https://arctichealth.org/en/permalink/ahliterature24641
Source
Drugs Exp Clin Res. 1992;18 Suppl:45-50
Publication Type
Article
Date
1992
Author
J. Musianowycz
F. Judmajer
D. Manfreda
P. Spängler
H. Albrecht
J. Hoffmann
D. Meijer
Author Affiliation
Allgem. öffentl. Krankenhaus des Landes Kärnten in Klagenfurt, Austria.
Source
Drugs Exp Clin Res. 1992;18 Suppl:45-50
Date
1992
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Alkaloids - adverse effects - therapeutic use
Antineoplastic Agents, Phytogenic - adverse effects - therapeutic use
Dose-Response Relationship, Drug
Female
Humans
Injections, Intramuscular
Injections, Intravenous
Male
Middle Aged
Neoplasms - complications - drug therapy
Pain - drug therapy - etiology
Research Support, Non-U.S. Gov't
Tumor Markers, Biological
Abstract
Phase II of clinical studies was performed on 70 patients, ranging in age from 14 to 80 years, (27 male, 43 female) to determine the appropriate dose range for Ukrain and the clarification of dose/response relationships, in order to provide an optimal background for wider therapeutic trials. The following parameters were studied: physiological (pulse, blood pressure, temperature); biochemical, haematological and immunological. Electrolytes and trace elements were investigated, as well as neopterin, tumour markers, immune complexes, non specific blocking factors, development of tumours and metastases in quantitative respects (by X-ray, CT, scintigrams and US). The patients' general conditions were also assessed. Ukrain was given intramuscularly or intravenously every one, two, three, four or five days, or according to other schemata, in the dose range of 2.5, 5, 10, 15, 20 or 25 mg increasing (2.5 to 25 mg per injection), decreasing (25 to 2.5 mg per injection) and stable (5, 10, 15, 20 or 25 mg per injection). Duration of one course of therapy was between 10 days and 90 days. Intervals between courses ranged from 7 days to 3 months. In order to find dose/duration/interval/response-relationships, some cases were treated after chemoradiotherapy, some as adjuvant therapy to chemo-radiotherapy and alternatives such as iscador, and some as monotherapy. All patients were at terminal stages of their disease.
PubMed ID
1305043 View in PubMed
Less detail

The effects of thiophosphoric acid (Ukrain) on cervical cancer, stage IB bulky.

https://arctichealth.org/en/permalink/ahliterature24636
Source
Drugs Exp Clin Res. 1992;18 Suppl:69-72
Publication Type
Article
Date
1992
Author
P. Pengsaa
W. Wongpratoom
V. Vatanasapt
B. Udomthavornsuk
E. Mairieng
V. Tangvorapongchai
M. Pesi
S. Krusan
V. Boonvisoot
J W Nowicky
Author Affiliation
Department of Obstectrics and Gynaecology, Faculty of Medicine, Khon Kaen University, Thailand.
Source
Drugs Exp Clin Res. 1992;18 Suppl:69-72
Date
1992
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - drug therapy - immunology
Adult
Alkaloids - adverse effects - therapeutic use
Antineoplastic Agents, Phytogenic - adverse effects - therapeutic use
B-Lymphocytes - drug effects
Carcinoma, Squamous Cell - drug therapy - immunology - surgery
Combined Modality Therapy
Female
Humans
Hysterectomy
Injections, Intramuscular
Middle Aged
T-Lymphocytes - drug effects
Uterine Cervical Neoplasms - drug therapy - immunology - surgery
Abstract
This study was carried out to determine the clinical and immune response of a stage IB voluminous uterine cervical cancer to thiophosphoric acid alkaloid derivatives from Chelidoniium majus L. (Ukrain). The drugs were administered 10 mg intramuscularly every other day, for up to 10 injections. The two largest diameters and tumour volumes were measured and laboratory and immunological tests were performed before and after Ukrain administration. The patients were then operated on with type III Piver's radical hysterectomy. Three out of nine eligible cases had partial responses while six cases remained stable. Decreased total B lymphocytes and suppressor T lymphocytes were observed as well as increased total numbers of T lymphocytes and helper T lymphocytes. There was no single case of clinical or haematological toxicity apart from mild nausea. Two patients were treated with adjuvant radiotherapy due to lymphatic involvement and all nine patients were still alive at least six months after follow-up.
PubMed ID
1305048 View in PubMed
Less detail

Influence of Ukrain on patients with surgically treated breast cancer. Part I. Clinical and laboratory parameters.

https://arctichealth.org/en/permalink/ahliterature22896
Source
Drugs Exp Clin Res. 1996;22(3-5):135-8
Publication Type
Article
Date
1996
Author
K N Uglyanica
K A Fomin
L I Nefyodov
J W Nowicky
W J Brzosko
A. Jankowski
Author Affiliation
Medical Institute, Grodno, Belarus.
Source
Drugs Exp Clin Res. 1996;22(3-5):135-8
Date
1996
Language
English
Publication Type
Article
Keywords
Alkaloids - adverse effects - therapeutic use
Antineoplastic Agents - therapeutic use
Breast Neoplasms - blood - drug therapy - surgery
Combined Modality Therapy
Female
Follow-Up Studies
Hematologic Tests
Humans
Middle Aged
Abstract
Studies were undertaken to evaluate the influence of Ukrain on clinical and laboratory parameters in ten patients with breast cancer treated with the drug in the preoperative phase. The control group was composed of eight patients of similar age and advancement of the disease who did not receive Ukrain before mastectomy. Data from the present studies indicate that the drug is distinctly helpful from the surgical viewpoint by increasing tumour hardness and enlargement of metastatic lymph nodes. Furthermore, treatment with it is fully safe, with no side effects or allergic reactions.
PubMed ID
8899316 View in PubMed
Less detail

Prednisolone does not reduce withdrawal headache: a randomized, double-blind study.

https://arctichealth.org/en/permalink/ahliterature77826
Source
Neurology. 2007 Jul 3;69(1):26-31
Publication Type
Article
Date
Jul-3-2007
Author
Bøe Magne G
Mygland Ase
Salvesen Rolf
Author Affiliation
Department of Neurology, Sorlandet Hospital, Kristiansand, Norway. magne.geir.boe@sshf.no
Source
Neurology. 2007 Jul 3;69(1):26-31
Date
Jul-3-2007
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Analgesics - adverse effects - therapeutic use
Anxiety - etiology
Combined Modality Therapy
Depression - drug therapy - etiology
Double-Blind Method
Drug Administration Schedule
Ergot Alkaloids - adverse effects - therapeutic use
Female
Headache Disorders, Secondary - chemically induced - drug therapy
Humans
Male
Medical Records
Middle Aged
Migraine Disorders - complications - drug therapy
Norway - epidemiology
Prednisolone - administration & dosage - therapeutic use
Prospective Studies
Substance Withdrawal Syndrome - drug therapy - etiology - therapy
Tension-Type Headache - complications - drug therapy
Treatment Failure
Tryptamines - adverse effects - therapeutic use
Abstract
INTRODUCTION: Medication overuse headache is a condition where abrupt drug withdrawal is considered the treatment of choice. OBJECTIVE: To study whether prednisolone given orally the first 6 days after medication withdrawal reduces headache intensity during the same period. METHODS: From August 2003 through November 2005, we included patients aged 18 to 70 years with probable medication overuse headache. The study was randomized, double-blind, and placebo controlled. The patients were hospitalized for 3 days to start medication withdrawal. They were randomly assigned to receive prednisolone 60 mg on days 1 and 2, 40 mg on days 3 and 4, and 20 mg on days 5 and 6 (Group A) or placebo tablets for 6 days (Group B). Headache intensity was recorded in a diary for a month before withdrawal (baseline) and throughout the study period of 28 days. The primary endpoint was a calculated mean headache (MH), based on number of days with headache and mean intensity the first 6 days after withdrawal. RESULTS: We included 26 men and 74 women. Sixty-five had migraine, 13 had tension-type headache, and 22 had both migraine and tension-type headache. Baseline headache days were 25.4 (CI 24.3 to 26.4). Baseline MH was 1.6 (CI 1.41 to 1.69). Fifty-one received Regimen A, and 49 received Regimen B. Baseline features were similar. During the first 6 days after withdrawal, headache was similar in Groups A and B (MH 1.48 [CI 1.28 to 1.68] vs 1.61 [CI 1.41 to 1.82], p = 0.34). CONCLUSION: Prednisolone has no effect on withdrawal headache in unselected patients with chronic daily headache and medication overuse.
Notes
Comment In: Neurology. 2007 Jul 3;69(1):14-517606877
PubMed ID
17475943 View in PubMed
Less detail

Preliminary studies on the effect of Ukrain (Tris(2-([5bS-(5ba,6b,12ba)]- 5b,6,7,12b,13,14-hexahydro-13-methyl[1,3] benzodioxolo[5,6-v]-1-3- dioxolo[4,5-i]phenanthridinium-6-ol]-Ethaneaminyl)Phosphinesulfide.6HCl ) on the immunological response in patients with malignant tumours.

https://arctichealth.org/en/permalink/ahliterature24638
Source
Drugs Exp Clin Res. 1992;18 Suppl:55-62
Publication Type
Article
Date
1992
Author
J. Danilos
W. Zbroja-Sontag
E. Baran
L. Kurylcio
L. Kondratowicz
L. Jusiak
Author Affiliation
Hospital for Obstetrics and Gynaecology, Lublin, Poland.
Source
Drugs Exp Clin Res. 1992;18 Suppl:55-62
Date
1992
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - drug therapy - immunology
Adult
Alkaloids - adverse effects - therapeutic use
Antineoplastic Agents, Phytogenic - adverse effects - therapeutic use
Breast Neoplasms - drug therapy - immunology
Bronchial Neoplasms - drug therapy - immunology
Carcinoma - drug therapy - immunology
Female
Humans
Male
Melanoma - drug therapy - immunology
Middle Aged
Neoplasms - drug therapy - immunology
Ovarian Neoplasms - drug therapy - immunology
Rosette Formation
Skin Neoplasms - drug therapy - immunology
T-Lymphocytes - drug effects - immunology
Uterine Neoplasms - drug therapy - immunology
Abstract
Preliminary clinical observations and studies on immunological response-indicators were made in eight patients with malignant tumours, who had been administered parenteral injections of Ukrain. The results suggest that the preparation is a non-toxic immunostimulator inducing production of thymodependent T lymphocytes. The preparation improves general health of patients, has anti-allergic action, and sedative and anti-inflammatory effects. It can inhibit growth of malignant tumours.
PubMed ID
1305046 View in PubMed
Less detail

Results of Ukrain monotherapy of prostate cancer.

https://arctichealth.org/en/permalink/ahliterature19822
Source
Drugs Exp Clin Res. 2000;26(5-6):191-3
Publication Type
Article
Date
2000
Author
K N Uglyanitsa
N A Nechiporenko
L I Nefyodov
Y M Doroshenko
W. Brzosko
W. Nowicky
Author Affiliation
Oncology Department, Higher Medical School, ul Gorkogo 80, 230015 Grodno, Belarus.
Source
Drugs Exp Clin Res. 2000;26(5-6):191-3
Date
2000
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Alkaloids - adverse effects - therapeutic use
Antineoplastic Agents, Phytogenic - adverse effects - therapeutic use
Humans
Immunity, Cellular - drug effects
Male
Middle Aged
Prostatic Neoplasms - blood - drug therapy
Abstract
This study included 15 patients with newly diagnosed prostate cancer with an average age of 71 years (62-85 years). The patients received Ukrain at a total dose of 100 mg (10 mg intravenously every second day, 10 injections altogether). After two to three injections of Ukrain, all the patients noted considerable subjective improvements in their state. Ukrain increased the amount of total T-lymphocytes, including "active" T-lymphocytes, decreased the content of T-suppressors and increased that of T helpers, correspondingly raising the T helper/T-suppressor ratio. Our results undoubtedly indicate the efficacy of Ukrain in the treatment of prostate cancer.
PubMed ID
11345026 View in PubMed
Less detail

15 records – page 1 of 2.